Results 191 to 200 of about 54,156 (279)

Multimodal assessment of treatment with proprotein convertase subtilisin/kexin type 9 inhibitors combined with statins for regulating coronary artery plaque regression in patients with chronic/acute coronary syndrome: A meta-analysis. [PDF]

J Int Med Res
Yuan D, Cheng T, Cao Z, Wang F, Wang Y.
europepmc   +1 more source

Subtilisin NAT

JOURNAL OF THE BREWING SOCIETY OF JAPAN, 1993
openaire   +2 more sources

Articles of Significant Interest in This Issue. [PDF]

Appl Environ Microbiol
europepmc   +1 more source

Familial Hypercholesterolaemia and the Risk of Cardiovascular Events. [PDF]

Cureus
Conchinha A, Rodrigues A, Pack T, Cunha S, Santos A.   +4 more
europepmc   +1 more source

Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer’s disease: A genetic and proteomic multi-cohort study

, 2019
Cynthia Picard, Alexandre Poirier, Stéphanie A.H. Bélanger, Anne Labonté, Daniel Auld, Judes Poirier   +5 more
openalex   +2 more sources

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: A Novel Therapy in the Treatment of Cholesterol Crystal Embolism-Induced Kidney Injury. [PDF]

Kidney Med
Strimaitis BJ, Francis L, O'Sullivan ED.
europepmc   +1 more source

Treatment with PCSK9 monoclonal antibodies is associated with discontinuation of oral lipid lowering therapy. [PDF]

Eur Heart J Qual Care Clin Outcomes
Engebretsen I, Ødegaard KM, Halvorsen S, Bugge C, Kristiansen IS, Støvring H, Munkhaugen J.   +6 more
europepmc   +1 more source

Expression of pro- and anti-inflammatory cytokines during anti-proprotein convertase subtilisin/kexin type 9 therapy in patients with statin-resistant familial hypercholesterolemia [PDF]

Julieta D. Morales-Portano, Rafael Trujillo-Cortés, Bricia Roa-Martínez, Rebeca Pérez‐Cabeza de Vaca, Silvia García, Paul Mondragón‐Terán, Juan Antonio Suárez‐Cuenca   +6 more
openalex   +1 more source

A study of extended lipid profile in patients with acute coronary syndrome: Focus on Lipoprotein(a) and PCSK9. [PDF]

Int J Cardiol Cardiovasc Risk Prev
Kumar P, Prajapathi S, Singh A, Pradhan A, Shukla A, Bhandari M, Sharma A, Vishwakarma P, Chaudhary G, Chandra S, Sethi R, Dwivedi S, Puri R.   +12 more
europepmc   +1 more source

Blocking PCSK9 suppresses hepatocellular carcinoma immune escape by decreasing FLI1-mediated SPP1 and PD-L1 expression. [PDF]

J Immunother Cancer
Hu C, Qin M, Lai W, Zhou H, Yuan C, Liu Y, Dai Y, Yang M, Hu M, Wang X, Luo M, Zhang R, Li G.   +12 more
europepmc   +1 more source